Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10653)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2014 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Song M, Ang TL. Second and third line treatment options for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i6/1517.htm |
| Number | Citing Articles |
| 1 |
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy. Journal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
|
| 2 |
Adeola O Adebisi, Barbara R Conway. Modification of Drug Delivery to Improve Antibiotic Targeting to the Stomach. Therapeutic Delivery 2015; 6(6): 741 doi: 10.4155/tde.15.35
|
| 3 |
Seung Woo Lee, Sung Jin Moon, Sae Hee Kim, Sung Hee Jung, Kyung Ho Song, Sun Moon Kim, Jae Kyu Sung, Dong Soo Lee. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine 2020; 99(38): e22137 doi: 10.1097/MD.0000000000022137
|
| 4 |
Guang-Hong Jheng, I-Chen Wu, Hsiang-Yao Shih, Meng-Chieh Wu, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Wen-Hung Hsu, Chi-Tan Hu, Ming-Jong Bair, Chao-Hung Kuo, Deng-Chyang Wu, Ping-I Hsu. Comparison of Second-Line Quadruple Therapies with or without Bismuth forHelicobacter pyloriInfection. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/163960
|
| 5 |
Ashutosh Gupta, Shiran Shetty, Srinivas Mutalik, Raghu Chandrashekar H, Nandakumar K, Elizabeth Mary Mathew, Abhishek Jha, Brahmeshwar Mishra, Siddheesh Rajpurohit, Gundawar Ravi, Moumita Saha, Sudheer Moorkoth. Treatment of H. pylori infection and gastric ulcer: Need for novel Pharmaceutical formulation. Heliyon 2023; 9(10): e20406 doi: 10.1016/j.heliyon.2023.e20406
|
| 6 |
Kenichiro Okimoto, Makoto Arai, Keiko Saito, Shoko Minemura, Daisuke Maruoka, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Chisato Ishii, Shota Murata, Masaharu Watanabe, Fumio Nomura, Osamu Yokosuka. Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. International Scholarly Research Notices 2014; 2014: 1 doi: 10.1155/2014/631501
|
| 7 |
Hyun Chul Lim, Yong Jae Lee, Byoungrak An, Seung Woo Lee, Yong Chan Lee, Byung Soo Moon. Rifabutin‐based High‐dose Proton‐pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori. Helicobacter 2014; 19(6): 455 doi: 10.1111/hel.12147
|
| 8 |
Enrique Rodríguez de Santiago, Carlos Martín de Argila de Prados, Hector Miguel Marcos Prieto, Miguel Ãngel Jorge Turrión, Eva Barreiro Alonso, Alvaro Flores de Miguel, Cristobal de la Coba Ortiz, Carlos Rodríguez Escaja, Gustavo Pérez Álvarez, Carlos Ferre Aracil, Lara Aguilera Castro, Ana García García de Paredes, Antonio Rodríguez Pérez, Agustin Albillos Martínez. Limited effectiveness with a 10‐day bismuth‐containing quadruple therapy (Pylera®) in third‐line recue treatment for Helicobacter pylori infection. A real‐life multicenter study. Helicobacter 2017; 22(5) doi: 10.1111/hel.12423
|
| 9 |
Stella I. Smith, Abraham Ajayi, Tolulope F. Jolaiya, Utibeima Essiet. Prevalence, diagnosis and treatment of Helicobacter pylori infection in Nigeria. Nigerian Journal of Gastroenterology and Hepatology 2022; 14(1): 2 doi: 10.4103/njgh.njgh_10_22
|
| 10 |
Rajmohan Rammohan, Sai Greeshma Magam, Melvin Joy, Dilman Natt, Achal Patel, Abhishek Tadikonda, Jiten Desai, Susan Bunting , Robert M Yost , Olawale Akande, Paul Mustacchia. Unpacking the Racial Gap: Helicobacter pylori Infection Clearance Among Different Racial Groups. Cureus 2023; doi: 10.7759/cureus.43080
|
| 11 |
Yoshihiro Hirata, Takako Serizawa, Satoki Shichijo, Nobumi Suzuki, Kosuke Sakitani, Yoku Hayakawa, Atsuo Yamada, Kazuhiko Koike. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. International Journal of Infectious Diseases 2016; 51: 66 doi: 10.1016/j.ijid.2016.08.019
|
| 12 |
I-Ting Wu, Seng-Kee Chuah, Chen-Hsiang Lee, Chih-Ming Liang, Lung-Sheng Lu, Yuan-Hung Kuo, Yi-Hao Yen, Ming-Luen Hu, Yeh-Pin Chou, Shih-Cheng Yang, Chung-Mou Kuo, Chung-Huang Kuo, Chun-Chih Chien, Yu-Shao Chiang, Shue-Shian Chiou, Tsung-Hui Hu, Wei-Chen Tai. Five-year sequential changes in secondary antibiotic resistance of <italic>Helicobacter pylori</italic> in Taiwan. World Journal of Gastroenterology 2015; 21(37): 10669-10674 doi: 10.3748/wjg.v21.i37.10669
|
| 13 |
Javier P. Gisbert. Rifabutin for the Treatment of Helicobacter pylori Infection: A Review. Pathogens 2020; 10(1): 15 doi: 10.3390/pathogens10010015
|
| 14 |
Leila Manzouri, Farzaneh Zarei, Narjes Niazi, Moslem Sedaghattalab. Comparison of the Success Rate of Quadruple and Triple Antibiotic Therapy in Eradicating Helicobacter pylori Infection in Southwest of Iran: A Randomized Clinical Trial. International Journal of Infection 2017; 4(3) doi: 10.5812/iji.15610
|
| 15 |
Tiing Leong Ang, Kwong Ming Fock, Daphne Ang, Andrew Boon Eu Kwek, Eng Kiong Teo, Subbiah Dhamodaran. The Changing Profile of Helicobacter pylori Antibiotic Resistance in Singapore: A 15‐Year Study. Helicobacter 2016; 21(4): 261 doi: 10.1111/hel.12291
|
| 16 |
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
|
| 17 |
Ying An, Ya Wang, Shuang Wu, You-Hua Wang, Xing Qian, Zhen Li, Ying-Jun Fu, Yong Xie. Fourth-generation quinolones in the treatment of <i>Helicobacter pylori</i> infection: A meta-analysis. World Journal of Gastroenterology 2018; 24(29): 3302-3312 doi: 10.3748/wjg.v24.i29.3302
|
| 18 |
Priscila Baptistella Yazbek, Ariane Biolcati Trindade, Chung Man Chin, Jean Leandro dos Santos. Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori. Digestive Diseases and Sciences 2015; 60(10): 2901 doi: 10.1007/s10620-015-3712-y
|
| 19 |
Ilaria M. Saracino, Matteo Pavoni, Angelo Zullo, Giulia Fiorini, Laura Saccomanno, Tiziana Lazzarotto, Guido Antonelli, Rossana Cavallo, Claudio Borghi, Dino Vaira. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020; 81: 50 doi: 10.1016/j.ejim.2020.06.029
|
| 20 |
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistance. Alimentary Pharmacology & Therapeutics 2016; 43(4): 514 doi: 10.1111/apt.13497
|
| 21 |
Anil John, Saad Al Kaabi, Sanjay Doiphode, Prem Chandra, Manik Sharma, Ragesh Babu, Rafie Yacoub, Moutaz Derbala. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?. Indian Journal of Gastroenterology 2015; 34(5): 404 doi: 10.1007/s12664-015-0604-1
|
| 22 |
Per Boye Hansen, Milena Penkowa. RETRACTED ARTICLE: Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Supportive Care in Cancer 2017; 25(4): 1279 doi: 10.1007/s00520-016-3522-6
|
| 23 |
Yeon-Ji Kim, Woo Chul Chung. Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2019; 19(4): 225 doi: 10.7704/kjhugr.2019.0019
|
| 24 |
Peter Malfertheiner, Michael Selgrad. Helicobacter pylori. Current Opinion in Gastroenterology 2014; 30(6): 589 doi: 10.1097/MOG.0000000000000128
|
| 25 |
Mu Feng, Hilda Namanja-Magliano, Saranathan Rajagopalan, Tanmay Mishra, Rodrigo G. Ducati, Brett M. Hirsch, Libusha Kelly, Wendy Szymczak, Jorge Eduardo Fajardo, Simone Sidoli, Andras Fiser, William R. Jacobs, Vern L. Schramm. MAT Gain of Activity Mutation in Helicobacter pylori Is Associated with Resistance to MTAN Transition State Analogues. ACS Infectious Diseases 2023; 9(4): 966 doi: 10.1021/acsinfecdis.2c00644
|
| 26 |
Thomas Regnath, Olaf Raecke, Axel Enninger, Ralf Ignatius. Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter 2017; 22(1) doi: 10.1111/hel.12327
|
| 27 |
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. Journal of Primary Care & Community Health 2021; 12 doi: 10.1177/21501327211014087
|